We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research compound — not a dietary supplement
Navitoclax is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Navitoclax studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2014–2020.
Based on 5 studies · 1 meta-analysis
Confidence
ModerateBy outcome
The current evidence for Navitoclax is insufficient to assign an evidence score, based on 5 indexed studies, including 1 meta-analysis. An investigational Bcl-2/Bcl-xL inhibitor and one of the most-used research senolytics — it clears senescent 'zombie' cells in animal models. Striking preclinical data (rejuvenated aged stem cells, reduced tau pathology), but no human longevity trials and a serious dose-limiting toxicity: it crashes platelets (thrombocytopenia). An investigational drug, not a supplement. Representative study: PMID 25053389.
The commonly studied dose of Navitoclax is No validated longevity dose. Senolytic research is preclinical or uses intermittent dosing under strict trial monitoring (largely for the platelet toxicity). Oncology dosing is continuous and causes thrombocytopenia. Not appropriate for self-administration.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Last reviewed June 2026 · evidence from 5 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Navitoclax (ABT-263) — senolytic use
An investigational Bcl-2/Bcl-xL inhibitor and one of the most-used research senolytics — it clears senescent 'zombie' cells in animal models. Striking preclinical data (rejuvenated aged stem cells, reduced tau pathology), but no human longevity trials and a serious dose-limiting toxicity: it crashes platelets (thrombocytopenia). An investigational drug, not a supplement.
Navitoclax is a potent, well-characterized research senolytic with strong animal evidence (stem-cell rejuvenation, reduced tau pathology), but there are no human longevity trials and its Bcl-xL inhibition causes serious dose-limiting thrombocytopenia — so the longevity use is preclinical-only and high-risk.
Navitoclax (ABT-263) is an orally bioavailable small molecule that inhibits the anti-apoptotic Bcl-2-family proteins (Bcl-2, Bcl-xL, Bcl-w), tipping vulnerable cells into apoptosis.
In geroscience it is one of the most widely used research senolytics: senescent cells survive partly by overexpressing these pro-survival proteins, so blocking them selectively kills senescent cells.
The preclinical case is strong and influential — navitoclax cleared senescent cells and rejuvenated aged or irradiated hematopoietic and muscle stem cells in mice, and clearing senescent glial cells with it reduced tau-dependent neurodegeneration and cognitive decline in models.
It was originally developed as an anticancer agent and has been tested in oncology trials, so human pharmacology and toxicity are well characterized — which is exactly where the problem lies.
Its mechanism (Bcl-xL inhibition) causes a dramatic, dose-limiting drop in platelets (thrombocytopenia), because circulating platelets depend on Bcl-xL for survival.
This makes chronic senolytic use risky, and much current research focuses on next-generation, platelet-sparing designs (PROTAC degraders, galacto-conjugated 'navitoclax' prodrugs) to keep the senolytic benefit without the bleeding risk.
The honest picture: compelling animal senolytic data, no human longevity or healthspan trials, and a serious toxicity that limits real-world use. Navitoclax is an investigational drug used as a research tool, not a dietary supplement, and self-administration would be dangerous.
The score reflects strong preclinical senolytic evidence offset by zero human longevity data and a severe dose-limiting toxicity.
Navitoclax blocks anti-apoptotic Bcl-2-family proteins that senescent cells (and platelets) depend on for survival, triggering their apoptosis.
By removing the pro-survival shield of senescent cells, it selectively clears them, reducing the senescence-associated secretory phenotype (SASP) and chronic inflammation.
Circulating platelets rely on Bcl-xL for survival, so the same mechanism causes dose-limiting thrombocytopenia — the central safety problem.
How Navitoclax works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated longevity dose. Senolytic research is preclinical or uses intermittent dosing under strict trial monitoring (largely for the platelet toxicity). Oncology dosing is continuous and causes thrombocytopenia. Not appropriate for self-administration.
Can be taken without food
| Form | Type |
|---|---|
| 💊None established (investigational research compound) | Recommended |
| 💊Dasatinib + quercetin (D+Q); next-gen platelet-sparing senolytics in development | Alternative |
An investigational oncology drug used as a research senolytic — not available or safe as a supplement.
Minimum: 1 weeks
Optimal: 4 weeks
Cycling: Senolytic research uses intermittent 'hit-and-run' dosing, partly to limit the platelet toxicity — but no human longevity protocol is established.
Note: Investigational; senolytic dosing is intermittent and requires platelet monitoring.
Dose-response data unavailable. The current published research for Navitoclax does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Cleared senescent cells and rejuvenated aged/irradiated stem cells in mice — not shown in humans.
Clearing senescent glial cells reduced tau pathology and cognitive decline in models.
Bcl-xL inhibition crashes platelet counts — a dose-limiting toxicity and real bleeding risk.
Human use is in cancer trials; there are no human longevity/healthspan studies.
Avoid — thrombocytopenia plus anticoagulation is dangerous.
Avoid — cytotoxic investigational agent.
Research-use-only; not safe to self-administer.
Adds to thrombocytopenia/bleeding risk — dangerous combination.
Can raise navitoclax exposure and toxicity.
Tip: Dose-limiting on-target toxicity; requires platelet monitoring in trials.
Tip: Consequence of low platelets; avoid with anticoagulants.
Tip: Monitored in clinical trials.
Timing is flexible for Navitoclax — consistent daily use matters more than the time of day. Investigational agent; any senolytic dosing is intermittent and trial-monitored for platelet counts.
Navitoclax should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are thrombocytopenia (low platelets), bleeding / bruising, neutropenia / GI effects. Use caution if any of these apply to you: Bleeding disorders / thrombocytopenia; Concurrent anticoagulants/antiplatelets; Pregnancy / breastfeeding.
Fermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.